A citation-based method for searching scientific literature

Paul T C Wan, Mathew J Garnett, S Mark Roe, Sharlene Lee, Dan Niculescu-Duvaz, Valerie M Good, C Michael Jones, Christopher J Marshall, Caroline J Springer, David Barford, Richard Marais. Cell 2004
Times Cited: 2015

Zhan Yao, Yijun Gao, Wenjing Su, Rona Yaeger, Jessica Tao, Na Na, Ying Zhang, Chao Zhang, Andrey Rymar, Anthony Tao, Neilawattie M Timaul, Rory Mcgriskin, Nathaniel A Outmezguine, HuiYong Zhao, Qing Chang, Besnik Qeriqi, Mariano Barbacid, Elisa de Stanchina, David M Hyman, Gideon Bollag, Neal Rosen. Nat Med 2019
Times Cited: 89

List of shared articles

Times cited

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
Shivshankari Rajkumar, Diana Berry, Kayla A Heney, Colton Strong, LeeAnn Ramsay, Mathieu Lajoie, Rached Alkallas, Tan-Trieu Nguyen, Cameron Thomson, Mozhdeh Ahanfeshar-Adams,[...]. Cell Rep 2022

BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.
Ioannis Tsamis, Georgia Gomatou, Stavroula Porfyria Chachali, Ioannis Panagiotis Trontzas, Vasileios Patriarcheas, Emmanouil Panagiotou, Elias Kotteas. Clin Transl Oncol 2022

RAS pathway regulation in melanoma.
Amira Al Mahi, Julien Ablain. Dis Model Mech 2022

BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences.
Aphrothiti J Hanrahan, David B Solit. Cancer Res 2022

Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.
Jeff Owsley, Matthew K Stein, Jason Porter, Gino K In, Mohamed Salem, Steven O'Day, Andrew Elliott, Kelsey Poorman, Geoffrey Gibney, Ari VanderWalde. Exp Biol Med (Maywood) 2021